Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Central Dogma01:20

The Central Dogma

21.0K
The central dogma explains the flow of genetic information from DNA nucleotides to the amino acid sequence of proteins.
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
21.0K
Cancer Vaccines01:30

Cancer Vaccines

348
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
348
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

45.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.8K
Recombinant DNA01:09

Recombinant DNA

93.8K
Overview
93.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-treatment Gut Microbiome Diversity and Function Linked to Cytotoxic and Natural Killer Cell Immune Responses after N-803 Treatment in People with HIV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Antiretroviral therapy blocks natural selection on protective and disease-susceptible HLA-B alleles in HIV-1 infection.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Determination of Adult Critical Care Physician Core Knowledge and Skills: Results of a Multidisciplinary, Modified Delphi Process.

Critical care medicine·2025
Same author

UV-vis-NIR magnetic linear dichroism: a powerful complement to MCD for f-block electronic structure.

Chemical science·2025
Same author

Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._.

Communications medicine·2025
Same author

From Radiomics to Generative Models: Evaluating Early Radiation Effects in Metastatic Brain Lesions.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025

Related Experiment Video

Updated: Jun 19, 2025

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
11:38

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

10.5K

Biotech's role in advancing HIV vaccine development.

Roger Tatoud1, Christian Brander2, Carey Hwang3

  • 1Origena Consulting, Ferney Voltaire, France.

Emerging Microbes & Infections
|July 23, 2024
PubMed
Summary

Developing an effective HIV vaccine remains challenging after 40 years. Startup biotech firms now lead HIV vaccine research but face funding and interest hurdles, requiring new support strategies.

Keywords:
HIVHIV vaccinebiotechpharmaceutical industryresearch and development

More Related Videos

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

7.8K
New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
09:27

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

11.2K

Related Experiment Videos

Last Updated: Jun 19, 2025

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
11:38

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

10.5K
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

7.8K
New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
09:27

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

11.2K

Area of Science:

  • Virology
  • Immunology
  • Biotechnology

Background:

  • HIV vaccine development has faced significant challenges for over four decades, with all efficacy trials yielding disappointing results.
  • The field has regressed to the discovery phase, creating uncertainty regarding large pharmaceutical companies' future involvement in HIV vaccine research.
  • The current HIV vaccine landscape is primarily driven by startup biotechnology firms, facing numerous obstacles.

Purpose of the Study:

  • To explore the multifaceted challenges confronting biotechnology firms in HIV vaccine development.
  • To identify essential support mechanisms required for the sustained involvement of biotech companies in this critical research area.
  • To propose a strategic approach for advancing HIV vaccine development by integrating insights from both pharmaceutical and biotech sectors.

Main Methods:

  • This viewpoint synthesizes current challenges and proposes solutions based on an analysis of the HIV vaccine landscape.
  • It leverages insights from both the pharmaceutical and biotechnology industries to inform proposed strategies.
  • The approach involves examining obstacles such as evolving prevention methods, declining research interest, and funding difficulties.

Main Results:

  • Startup biotech firms are the primary drivers of current HIV vaccine research.
  • Key obstacles include evolving HIV prevention strategies, waning research interest, and securing sustainable funding.
  • The study highlights the need for enhanced communication and innovation within the sector.

Conclusions:

  • Continued progress in HIV vaccine development necessitates robust support for emerging biotech firms.
  • A multi-faceted approach involving strategic funding, fostering innovation, and improved communication is crucial.
  • Collaboration between pharmaceutical and biotech sectors is vital for overcoming long-standing challenges in creating an effective HIV vaccine.